Section Arrow
ZURA.NASDAQ
- Zura Bio Limited
Quotes are at least 15-min delayed:2026/08/11 17:12 EDT
After Hours
Last
 5.54
-0.02 (-0.36%)
Bid
5.55
Ask
5.8
High 5.67 
Low 5.54 
Volume 21.84K 
Regular Hours (Closed)
Last
 5.56
-0.07 (-1.24%)
Day High 
5.98 
Prev. Close
5.63 
1-M High
6.01 
Volume 
1.60M 
Bid
5.55
Ask
5.8
Day Low
5.55 
Open
5.7 
1-M Low
4.85 
Market Cap 
534.84M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 5.6 
20-SMA 5.47 
50-SMA 4.83 
52-W High 7.44 
52-W Low 1.6604 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.09/-0.91
Enterprise Value
534.84M
Balance Sheet
Book Value Per Share
2.28
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.3055+0.0331+12.15%-- 
After Hours 0.325 +0.0195 +6.38%
TENXTenax Therapeutics1.62+0.245+17.82%-- 
After Hours 1.64 +0.02 +1.23%
PDSBPDS Biotechnology Corp0.2568-0.4743-64.87%-- 
After Hours 0.253 -0.0038 -1.48%
ABCLAbCellera Biologics9.76+0.42+4.50%-- 
After Hours 9.3185 -0.4415 -4.52%
DRMADermata Therapeutics Inc1.08-0.04-3.57%-- 
After Hours 1.5408 +0.4608 +42.67%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.